Veracyte Interest Expense 2011-2025 | VCYT

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Veracyte

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
9.18 M	4.65 M	254 K	229 K	677 K	1.96 M	4.94 M	2.76 M	378 K	439 K	233 K	280 K	819 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
9.18 M	229 K	2.06 M

Quarterly Interest Expense Veracyte

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-4.06 M	6.52 M	4.52 M	-	4.83 M	2.76 M	2.75 M	-	1.97 M	-226 K	2.41 M	-	805 K	1.09 M	784 K	-	1.2 M	63 K	53 K	-	55 K	65 K	55 K	-	58 K	235 K	303 K	-	498 K	481 K	448 K	-	815 K	808 K	800 K	-	799 K	785 K	367 K	-	92 K	90 K	89 K	-	114 K	113 K	111 K	-	126 K	5 K	-1 M	-	1 K	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
6.52 M	-4.06 M	794 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
Arbutus Biopharma Corporation ABUS	459 K	$ 4.79	2.35 %	$ 795 M	Canada
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Aeglea BioTherapeutics AGLE	-20.7 M	-	-	$ 1.01 B	USA
Aclaris Therapeutics ACRS	2.95 M	$ 3.04	4.83 %	$ 235 M	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
AlloVir ALVR	1.19 M	-	4.14 %	$ 49.1 M	USA
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
BioVie BIVI	4.3 M	$ 1.27	-3.05 %	$ 1.88 M	USA
Aptevo Therapeutics APVO	472 K	$ 0.93	-8.81 %	$ 257 K	USA
Athersys ATHX	103 K	-	3.77 %	$ 22.4 M	USA
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
BioDelivery Sciences International BDSI	-6 K	-	-4.8 %	$ 255 M	USA
BeiGene, Ltd. BGNE	-12.6 M	-	0.49 %	$ 251 B	Cayman-islands
Bellicum Pharmaceuticals BLCM	2.66 M	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	910 K	-	-7.31 %	$ 87 M	USA
bluebird bio BLUE	16.4 M	-	-	$ 546 M	USA
Ascendis Pharma A/S ASND	65.5 M	$ 212.81	1.71 %	$ 5 B	Danmark
Calithera Biosciences CALA	2.65 M	-	-10.95 %	$ 876 K	USA
Can-Fite BioPharma Ltd. CANF	227 K	$ 0.18	-25.03 %	$ 392 M	Israel
Catalyst Biosciences CBIO	1.04 M	$ 12.37	2.06 %	$ 814 M	USA
Cerevel Therapeutics Holdings CERE	10.6 M	-	-	$ 7.29 B	USA
Alterity Therapeutics Limited ATHE	2.28 K	$ 3.1	0.16 %	$ 7.46 B	Australia
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Adaptimmune Therapeutics plc ADAP	-807 K	-	-15.15 %	$ 60.3 M	Britain
Celsion Corporation CLSN	5.03 M	-	-6.63 %	$ 13.9 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Catalyst Pharmaceuticals CPRX	21.1 M	$ 24.45	0.91 %	$ 2.9 B	USA
Amphastar Pharmaceuticals AMPH	4.08 M	$ 26.81	1.36 %	$ 1.3 B	USA
Cortexyme CRTX	-102 K	-	-1.05 %	$ 67.1 M	USA
CTI BioPharma Corp. CTIC	13.1 M	-	-	$ 1.2 B	USA
Arena Pharmaceuticals ARNA	4.16 M	-	-6.81 %	$ 3.04 B	USA
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
Axon Enterprise AXON	286 M	$ 591.15	0.02 %	$ 44.8 B	USA
Aytu BioScience AYTU	-512 K	$ 2.53	-0.39 %	$ 15.9 M	USA
Celldex Therapeutics CLDX	927 K	$ 26.83	0.94 %	$ 1.73 M	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA